Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04318717 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

StatusRecruiting
PhasePhase 2
Started2020-05-29
View on ClinicalTrials.gov ↗
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.

Amendment record

Amended 15 times since 2020-03-20; most recent filed 2026-08-24. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-24
Amendment Study Status, Contacts/Locations v15
2026-05-22
Amendment Study Status, Study Design v14
2025-11-21
Amendment Study Status, Study Design, Outcome Measures, Contacts/Locations v13
2025-02-13
Amendment Study Status, Outcome Measures v12
2024-12-16
Amendment Study Status, Study Description v11
2023-11-21
Amendment Study Status v10
2023-02-08
Amendment Study Status v9
2022-02-07
Amendment Study Status, Study Design v8
2022-01-12
Amendment Study Status v7
2021-07-02
Amendment Study Status v6
2021-05-20
Amendment Study Status, Outcome Measures v5
2021-05-17
Amendment Study Status, Eligibility, Contacts/Locations v4
2020-09-08
Amendment Study Status, Arms and Interventions v3
2020-06-08
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2020-05-06
Amendment Study Status v1
2020-03-20
Original filing
Trial Details
NCT Number NCT04318717
Lead Sponsor Washington University School of Medicine
Conditions Mucosal Melanoma of the Head and Neck
Enrollment 20 participants
Start Date 2020-05-29
Primary Completion 2030-07-31 (estimated)
Study Completion 2032-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-27